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Verotoxin binding to its receptor, globotriaosyl
ceramide(Gb3) mediates the glomerular pathology of
hemolytic uremic syndrome, but Gb3 is expressed in both
tubular and glomerular cells. Gb3 within detergent-resistant
membranes, an index of glycolipid-cholesterol enriched lipid
rafts, is required for in vitro cytotoxicity. We found that
verotoxin 1 and 2 binding to human adult renal glomeruli is
detergent resistant, whereas the strong verotoxin binding to
renal tubules is detergent sensitive. Verotoxin binding to
pediatric glomeruli was detergent resistant but binding to
adult glomeruli was enhanced, remarkably for some samples,
by detergent extraction. Detergent-sensitive glomerular
components may provide age-related protection against
verotoxin glomerular binding. Mouse glomeruli remained
verotoxin unreactive after detergent extraction, whereas
tubular binding was lost. Cholesterol extraction induced
strong verotoxin binding in poorly reactive adult glomeruli,
suggesting cholesterol can mask Gb3 in glomerular lipid
rafts. Binding of the human immunodeficiency virus (HIV)
adhesin, gp120 (another Gb3 ligand) was detergent sensitive,
tubule-restricted, and inhibited by verotoxin B subunit
pretreatment, and may relate to HIV nephropathy. Our study
shows that differential membrane Gb3 organization in
glomeruli and tubules provides a basis for the age- and
glomerular-restricted pathology of hemolytic uremic
syndrome.
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The more rigid membrane domains of the liquid ordered
phase are easily demonstrable in model systems1 but the
relevance of such models in terms of normal cellular
physiology have frequently been questioned,2,3 primarily
due to the difficulty of isolation of such microdomains (or
‘lipid rafts’) from living cells. This is commonly achieved by
resistance to Triton detergent solubilization at 41C and
sucrose gradient separation.4,5 These extracted detergent-
resistant membrane (DRM) domains are enriched in
cholesterol, glycosphingolipids (GSLs), sphingomyelin and
glycophosphoinositol-linked membrane proteins,6,7 but re-
present a mixed pool, not representative of potential
individual domains in cell membranes. Although the exact
cell physiological parameter measured by detergent resistance
has yet to be precisely defined,8,9 this procedure provides a
useful tool for investigation of membrane dynamics in living
cells.10 Domains, which may be equivalent to the lo phase in
model membranes, have been shown in living cells by a
variety of staining procedures.11–15 Whatever their physiolo-
gical basis, DRMs are central in many transmembrane
signaling pathways16 and, in relation to the present studies,
play important roles in many aspects of microbial–host cell
interactions.17–19
Verotoxins are an Escherichia coli elaborated family of
subunit toxins comprising a single A subunit, which
inactivates ribosomal protein synthesis and a pentamer of B
subunits responsible for binding the GSL, globotriaosyl
ceramide Gala1-4Galß1-4 glucosyl ceramide (Gb3) also
known as the B cell marker CD77,20 and the pk blood group
antigen.21 Gb3 is primarily found in the kidney of man and
mice.22 Verotoxins are vasotoxins that target endothelial cells.
Infection in humans is gastrointestinal, and submucosal
blood vessels are the site of primary lesions following such
infections, which result in hemorrhagic colitis. Such infec-
tions and lesions spontaneously resolve in most cases, but in
a minor subset of individuals, primarily in the very young
and old, a second phase of pathology may occur.23 This is
termed hemolytic uremic syndrome (HUS),24 whereby
systemic verotoxemia targets the renal microvasculature to
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induce infarcts within the glomerulus and the ensuing
thrombocytopenia and hemolysis can yet be fatal.25 In the
mouse, no verotoxin-binding sites within the glomerulus can
be detected 26 and this is consistent with the fact that
systemic verotoxemia in the mouse results in tubular necrosis
rather than HUS.27
Human immunodeficiency virus (HIV) infection has been
associated with HUS susceptibility,28 and HIV transgenic
mice show nephropathy and abnormal renal Gb3 metabo-
lism.29 The HIV envelope glycoprotein, gp120, binds several
GSLs, including Gb3,
30 and a soluble Gb3 mimic inhibits HIV
infection and gp120-dependent membrane fusion.31 Nephro-
pathy is common in HIV/AIDS, and renal epithelial cells can
be infected by HIV32 to provide a viral reservoir.33
Gb3 can be found in DRMs in the plasma membrane of
cultured cells and mediate transmembrane signals.34–36 VT
cytotoxicity in cell culture is dependent on Gb3 presentation
within a DRM format.37–40 Cytotoxicity depends on the
retrograde transport of VT1 or VT2 from the cell surface to
the Golgi/ER40 for cytosolic transit of the A subunit.41 Non-
DRM plasma membrane Gb3 mediates binding and subse-
quent traffic to lysosomes for VT degradation.37,38 Our
present studies indicate that differential DRM expression of
Gb3 also plays a major age-related role in VT-induced renal
pathology in man.
The role played by Gb3 expression on renal glomerular
endothelial cells in the susceptibility to HUC following
gastrointestinal verocytotoxin-producing E. coli infection
remains to be clearly defined. Our early studies using direct
labeled VT1 showed selective binding of pediatric as opposed
to adult renal glomeruli,42 which correlates with the
incidence of HUS. However, later studies using indirect
immunostaining showed that VT1 stained some, and VT2 all,
adult glomeruli and that cholesterol depletion induced VT1
glomerular staining.43 We now confirm these results but
show that the differential glomerular/tubular VT binding is a
function of resistance to detergent extraction as a function of
age. These studies imply that the membrane organization of
Gb3 is different in tubular epithelial and glomerular
endothelial cells and that this changes with age such that
HUS susceptibility may be lipid raft-based.
RESULTS
Double labeling of human pediatric renal frozen tissue with
VT1 and VT2 showed strong VT2 glomerular binding with
(Figure 1a), or without (Figure 1b and c), coincident VT1
staining, according to sample. Samples with selective VT2
glomerular staining showed pronounced VT1 tubular bind-
ing. VT2 blood vessel staining was more prominent (arrows)
than VT1. Similar results were obtained by separate VT1 and
VT2 staining of serial pediatric renal sections (Figure 2).
Although VT1 glomerular was greater than tubular staining
(Figure 2A, a), VT2 glomerular staining was more pro-
nounced and VT2 tubular staining was also more significant
(cf. Figure 2A, a vs c).
Comparison of pediatric renal section staining with VT1
or VT2 before and after Triton extraction at 41C (cf. Figure
2A, a, c vs b, d), clearly showed that glomerular VT1 and VT2
staining are marginally affected by detergent extraction
(Figure 2A, b and d). In the serial sections shown, the same
two glomeruli are apparent (arrows) in each section. VT2
staining of both glomeruli is more pronounced than VT1.
For VT1 only, the right glomerulus is more extensively
stained than the left, consistent with the differential VT2
glomerular staining observed by double labeling in pediatric
(Figure 1) and adult43 renal sections. In untreated sections,
VT1 glomerular staining is particularly prevalent as we
reported.42 VT1 and VT2 blood vessel staining is seen (*).
VT2 tubular staining is greater than VT1. Following Triton
extraction, VT1 staining of the left glomerulus is enhanced
and staining of the right is unaffected (that is, detergent
resistant) but blood vessel staining is lost. The left
glomerulus, less well stained with VT1, is strongly stained
by VT2. VT2 glomerular staining is largely resistant to
detergent extraction but, similar to VT1, VT2 blood vessel
staining is lost. VT2 tubular binding is detergent sensitive.
In adult renal sections (Figure 2B), VT1 glomerular
staining is significantly less than that seen for pediatric
sections (though some pediatric glomeruli are less VT1-
reactive than others). Adult tubular VT1 staining is
remarkably increased relative to pediatric sections (Figure
2B, a and c). This strong VT1 tubular staining is virtually
eliminated in detergent-treated sections (Figure 2B, b and d)
but glomerular staining is increased. In serial sections, it can
be seen that the same glomerulus initially VT1/2 reactive can
become intensely bound by VT1 and VT2 following detergent
extraction (Figure 2B, b and d). Some adult samples
contained glomeruli preferentially reactive with VT1 (cf.
Figure 2C, a vs c). In this case, detergent extraction enhanced
VT2 staining (cf. Figure 2C, c vs d). In contrast, tubular VT1
and VT2 staining was entirely detergent sensitive (Figure 2C,
a, c vs b, d). In the more common samples in which VT2
Figure 1 | Comparison of VT1 and VT2 staining of human renal sections. Pediatric renal cortex frozen section double labeled with VT1
(blue) and VT2 (pink). (a) Glomerulus stained with both VT1 and VT2; (b, c) glomeruli and blood vessels (arrows) preferentially VT2 labeled.
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glomerular staining was predominant (Figure 2D), serial
sections showed that detergent extraction enhanced both
VT1 and VT2 glomerular staining.
For all adult sections tested, tubular staining was lost
following detergent extraction and glomerular staining was
increased (to a variable degree).
We had shown that treatment with b-methylcyclodextrin
(b-MCD) to extract cholesterol enhanced VT1 glomerular
binding.43 This was therefore compared with detergent
extraction (Figure 3). As expected, MCD extraction had no
effect on tubular VT1 staining and detergent extraction
eliminated tubular, and enhanced glomerular VT1 staining.
Figure 2 | Effect of tissue section Triton extraction on VT1 and VT2 human renal section staining. (A) Pediatric serial sections (a) VT1
staining, (b) VT1 staining of serial section after detergent extraction, (c) serial section VT2 staining, (d) serial section VT2 staining after
detergent extraction. The same two glomeruli are marked with arrows in each section and a small blood vessel marked with an asterisk in
each unextracted section. (B) Adult (83 years) frozen renal cortical sections stained with VT1. (a, c) Serial sections were stained without or (b,
c) with prior detergent extraction. Boxed glomerulus in a, b is expanded in c, d. Glomerular staining is enhanced but tubular staining was
removed after extraction. Image analysis showed glomerular staining was increased by 260±103% (n¼ 9), while tubular staining was
reduced to 23.6±5.6% (n¼ 7) by detergent extraction. (C) Renal cortex (60 years). Serial section staining: (a, b) VT1 or (c, d) VT2. (a, c)
Untreated or (b, d) after detergent extraction counterstained with hematoxylin and eosin. Arrows indicate the same glomerulus in each
panel. In this case VT1 shows stronger glomerular staining than VT2. Tubular, but not glomerular, staining is lost after detergent extraction.
Image analysis showed VT1 glomerular staining was increased by 117±21.9% (n¼ 5) and VT2 staining was increased by 179±49% (n¼ 8),
while VT1 tubular staining was reduced to 37.7±11.5% (n¼ 5) and VT2 to 18.2±7.7% (n¼ 5) by detergent extraction. (D) Adult (24 years)
serial renal sections were stained with (a, b) VT1 or (c, d) VT2. (a, c) Untreated or (b, d) after detergent extraction. The same glomerulus
(arrow) is seen in each panel. This glomerulus is more strongly stained by VT2, but after detergent extraction both VT1 and VT2 staining is
markedly enhanced (371.6±210% (n¼ 8), 159.6±52% (n¼ 9), respectively).
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Surprisingly however, MCD extraction increased VT1
glomerular staining more than detergent extraction (cf.
Figure 3c vs b and ). In sequential extractions of serial
sections (Figure 3g–p), MCD-induced glomerular staining
was largely detergent resistant. After detergent extraction,
MCD induction of VT1, but not VT2, glomerular binding
was still evident. Thus, even after detergent extraction, Gb3-
binding sites within the glomerulus can be hidden by
cholesterol.
As mouse renal glomeruli do not bind VT1 or VT2,26,44we
assessed the effect of detergent extract on mouse glomerular
binding (Figure 4). The intense VT1 and VT2 tubular
binding was largely eliminated by detergent extraction, but
the unstained glomeruli (Figure 4 a, c and e) remained
completely VT1/VT2 unreactive after detergent extraction
(Figure 4b, d and f).
Study of the renal binding of the HIV adhesin gp120,
which also binds Gb3
45 (among other GSLs46) served to
further emphasize the complex regulation of Gb3 receptor
function within the kidney. Gp120 bound exclusively to the
renal tubular epithelium (Figure 5A) and this binding was
significantly reduced when the sections were pretreated with
VT1 B subunit, suggesting that a large fraction of the gp120
renal binding is Gb3 mediated. Following detergent extrac-
tion, the gp120 tubular binding was lost (as for VT1, VT2).
However, unlike for VT1/2 staining, there was no induction
of gp120 glomerular binding (Figure 5b). Serial section
staining confirmed that while detergent extraction increased
VT1 staining of a glomerulus (Figure 2B) gp120 staining of
the same glomerulus remained negative. Thus, detergent
extraction has a selective effect to ‘unmask’ VT1 (VT2)
glomerular Gb3 binding.
DISCUSSION
Aglycone regulation of GSL receptor function, both by the
lipid moiety of the GSL itself, and by the membrane
Figure 3 | Comparison of bMCD and Triton extraction on VT1/VT2 adult renal section staining. (a–f and g–p) Serial frozen sections
(a–c) VT1 staining, (a) untreated, (b) detergent extracted, and (c) b-MCD extracted. (d–f) VT2 staining, (d) untreated, (e) detergent extracted,
(f) b-MCD extracted. Arrows indicate the same two glomeruli. Renal glomeruli show low VT1 and no VT2 binding. After detergent extraction
VT1/VT2 tubular staining is lost and glomerular staining is slightly enhanced. After b-MCD extraction, strong VT1/VT2 staining of all
glomeruli is seen but tubular staining is unaffected. Sequential extraction of serial sections: (g–k) VT1 staining, (l–p) VT2 staining; (g)
untreated, (h) b-MCD extracted, (i) detergent extracted after b-MCD extraction, (j) detergent extracted, (k) b-MCD extracted after detergent
extraction, (l) untreated, (m) b-MCD extracted, (n) detergent extracted after b-MCD extraction, (o) detergent extracted, (p) b-MCD extracted
after detergent extraction. MCD induces strong VT1 and VT2 glomerular binding, which is significantly detergent resistant. Detergent
extraction is less effective to induce VT1 than VT2 binding, but MCD is more effective for VT1 even after detergent extraction.
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environment has been described in many reports.47 Although
Gb3 is the only functional receptor for VT1 and VT2,
48 VT1
and VT2 can preferentially bind different Gb3 ‘lipid
assemblies’ in vitro, and following internalization, undergo
differential membrane retrograde trafficking to the Golgi and
ER in cultured cells.40 VT1 and VT2 recognize overlapping
epitopes within the Gb3 carbohydrate sequence,
43 and VT1
(but not VT2) binding to Gb3 within the renal glomerulus
43
and to Gb3 vesicle constructs
40 can be inhibited by excess
cholesterol.
The relevance of sucrose gradient separated DRMs in
normal cellular physiology remains a matter of debate. Such
DRMs, although useful to assess changing parameters of cell
membrane physiology, represent an amalgum of potentially
separate microdomains, which might be originally present in
the cell plasma membrane.10 However, detergent extraction/
resistance of tissue sections potentially represents a more
physiologically relevant probe of cellular/tissue DRMs, as the
residual antigens are, by definition, detergent resistant and
therefore, more representative of their original cellular
presentation and location. The use of this approach to
investigate differences in membrane domains in tissue
sections has not been previously used, but examination of
intracellular membranes of cultured cells according to
detergent resistance has been reported.37,40 Detergent extrac-
tion of tissue sections in situ may provide a new tool to
examine the role of lipid rafts in cellular physiology, and
perhaps more importantly, in disease. In simple model Gb3/
cholesterol DRM vesicles, we have found that a significant
fraction of the Gb3 is unavailable for ligand binding.
49,50 This
may provide a model of the undetected glomerular Gb3 that
we have found to be exposed following MCD treatment.
Resistance of membrane lipids to mild nonionic detergent
extraction is a measure of the relative strength of lateral
interaction within the membrane, as opposed to forming
mixed micellar complexes with the detergent. The interaction
of cholesterol with sphingolipids51 increases such lateral
Figure 4 | Effect of tissue section Triton extraction on VT1 and
VT2 mouse renal section staining. Serial frozen sections were
stained with VT1 (a–b, c–d) or VT2. (e–f) Untreated (a, c, e) or after
detergent extraction (b, d, f). Extensive VT1/2 tubular but not
glomerular staining is seen. After extraction the tubular staining is
largely lost and glomeruli remain unstained. By image analysis,
VT1/VT2 tubular staining was reduced to 18.4±1.4% (n¼ 4)/
46.7±11.7% (n¼ 7) following detergent extraction.
a b
c d
Figure 5 | HIV gp120– human renal tubular staining– effect of
Triton extraction and VT1B. (A) gp120 staining of adult kidney
frozen sections. Extensive tubular but not glomerular (arrows)
staining is seen. (B) Serial sections (a) gp120 immunostaining, (b)
gp120 immunostaining of serial section after Triton extraction, (c)
gp120 immunostaining, (d) gp120 immunostaining of serial
section after prior VT1B blockage. Same sample as in Figure 2B. By
image analysis, gp120 tubular staining was reduced to
15.3±11.7% (n¼ 6) following detergent extraction.
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interaction to promote resistance to detergent extraction.
Thus in glomerular endothelial cells, Gb3 shows stronger
lateral interactions within the membrane, likely with
cholesterol.
Gb3 can be found in cultured cell DRMs together with
tyrosine kinases involved in transmembrane signal-
ing.34,35,52,53 VT1 binding Gb3 within plasma membrane
DRMs results in the intracellular retrograde translocation of
the toxin to the Golgi/ER and cell killing, whereas binding to
non-DRM Gb3 results in the intracellular targeting of the
toxin to endosomes/lysosomes and degradation of the toxin
without cell killing.37,38 Thus, membrane organization of Gb3
is an important risk factor for VT cellular intoxication in
vitro. Our data suggest that it may also be an important risk
faction for the pathology of HUS.
In HUS, tubular necrosis is not a primary feature,54 but
rather glomerular occlusion/infarct. Children under 2 years
are at greatest risk following gastrointestinal verocytotoxin-
producing E. coli infection.55 We had previously shown that
pediatric renal glomeruli bind fluorescein isothiocyanate-
labeled VT1, whereas no binding to adult glomeruli was
seen,42 implying that receptor distribution could be a
primary risk factor for HUS.
This age-related binding was subsequently questioned by
VT1 immunohistochemical renal staining showing equal
glomerular staining of adult and pediatric renal samples.56
However, this binding was at 41C and was lost at 371C.
Binding at 41C provides a bias toward a membrane lipid
rigidity, which might not reflect physiological Gb3 presenta-
tion. We previously confirmed that fluorescein isothiocya-
nate-labeled VT1 did not bind adult glomeruli43 and find
that Alexa-labeled VT1 is also unreactive with adult
glomeruli (not shown). Previously,43 and in this study, we
find that native VT1 does bind to some adult glomeruli.
Thus, chemical fluorescent labeling of VT1 alters adult
glomerular reactivity.
In our immunohistochemical studies using unmodified
toxin (43 and this study), we find VT2 (and less VT1) binding
to adult glomeruli but the staining is less than that for
pediatric glomeruli. This supports a role for glomerular Gb3
binding in the incidence of HUS. In addition, adult
glomerular staining is variable, particularly for VT1,
suggesting that this could remain a basis for HUS suscept-
ibility. Our finding that detergent extraction can significantly
increase adult glomerular VT1 and VT2 binding, while
depleting tubular binding indicates that (i) VT binding to
non-DRM Gb3 in renal tubules may explain the relative lack
of tubular pathology in HUS and (ii) that the adult
glomerular VT1 and VT2 binding sites are significantly
protected from toxin binding by component(s) readily
susceptible to detergent extraction. Whether this is due to
interference by another GSL, such as the blocking by
sulfogalactosyl ceramide, we have shown for VT1 binding
to model Gb3 DRM membranes,
57 or a less specific exposure
mechanism, remains to be determined. Detergent extraction
has a similar effect on VT1 glomerular Gb3 binding as we
have reported for b-MCD,43 but our studies show that these
effects, although overlapping, are distinct in that MCD
increased VT1 glomerular staining more effectively than
detergent extraction and is effective even after detergent
extraction. Cholesterol is largely detergent resistant and
glomerular Gb3 within DRMs must still, in part, be
unavailable to bind VT until some cholesterol is removed.
Whatever the mechanism, this provides new insight into the
age-related incidence of HUS. As the degree of enhanced
VT1/VT2 glomerular binding, though always observed, was
variable between adult renal specimens, the protection
afforded by the non-DRM fraction may also be a variable
to consider in the incidence of VT-induced HUS, particularly
the elderly.
Human immunodeficiency virus infection has been
proposed as an HUS risk factor,28 and renal tubular Gb3 is
increased in HIV transgenic mice.29 Focal glomerulosclerosis/
tubulointerstitial disease is associated with HIV/AIDS(HI-
VAN)58 and gp120 binding to cultured glomerular epithelial,
mesangial, and endothelial cells can modulate growth.59–61
However, such glomerular interactions must be less prevalent
or less robust than the tubular epithelial gp120 binding we
observe. Gp120 binding can induce inflammatory cyto-
kines,62 but the relationship of the non-DRM tubular Gb3/
gp120 binding with HIVAN has yet to be established.
The lack of glomerular gp120 binding, as compared with
VT1/VT2, emphasizes the selectivity of aglycone modulation
of Gb3 receptor function, and the unique character of VT1/
VT2 glomerular Gb3 binding.
In conclusion, Gb3 is expressed in human renal tubules to
the same, or even greater63 levels than glomeruli. Strong VT
tubular binding in vitro is seen, yet VT-induced pathology is
restricted to the glomerulus. The marked distinction between
renal tubular non-DRM and glomerular DRM VT1/VT2-Gb3
binding provides a potential basis for this discrepancy, and
together with the crucial role we show glomerular cholesterol
to play, suggests that the glomerular nephropathy of HUS
may be lipid raft-based.
MATERIALS AND METHODS
Antibodies
Monoclonal antibody PH1, specific for the VT1 B subunit, has been
previously described.64 Rabbit anti-VT2e was supplied by C Gyles
(University of Guelph). Polyclonal rabbit anti-VT1 B 6869 was
prepared in our laboratory. R5 HIV-1 gp120, monoclonal antibody
(F425 B4a1) were obtained through the NIH AIDS Research and
Reference reagent program, Division of AIDs, NIAID, NIH. Biotin
conjugated goat anti-rat IgM serum and biotin conjugated goat anti-
rabbit Ig were from Jackson Immunoresearch Laboratories (West
Grove, PA, USA). Anti-human IgG peroxidase (raised in goat) was
purchased from Sigma, St Louis, MO, USA.
Ligands
VT1 was purified from recombinant E. coli strain JB28, as previously
described.65 VT1 B subunit was purified from E. coli strain JB120 as
described.66 VT2 was purified from E. coli strain R82pJES1-20DH5a,
kindly provided by Dr J Samuel (Texas A&M University).67 HIV-1
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Bal gp120 recombinant was obtained through the NIH AIDS
Research and Reference reagent program, Division of AIDs, NIAID,
NIH.
Tissue preparation
Human renal cortical tissue was harvested 5–10 h postmortem (due
to non-renal, non-infectious cause) with University of Toronto
Ethics Committee approval. Grossly normal appearing tissue was
excised, embedded in Tissue Tek OCT Compound (Sakura Finetek,
Torrence, CA, USA), and snap-frozen in liquid nitrogen. Frozen
tissue was then cryo sectioned (6 mm), and serial sections were
stored at 701C. Sections to be stained were dried overnight at
room temperature and all subsequent steps were performed in a
humid chamber. Mouse renal tissue was prepared as above
immediately after killing.
Triton extraction on renal tissue sections
For Triton X-100 extraction on renal tissue sections, the tissue
sections were kept on ice, washed once with 1% phosphate-buffered
saline (PBS), and incubated for 1 min in 1% Triton/PBS buffer. The
buffer was then removed. Sections were then immuno stained as
stated bellow.
VT staining of frozen kidney sections
Immunoperoxidase VT staining was performed at room tempera-
ture, as described43,68 with some modifications. Nine renal samples
were studied, but results are presented primarily for four samples in
which sufficient serial cryo sections allowed direct staining
comparison. Both Triton treated and untreated sections were
blocked for endogenous peroxidase using universal block (KPL)
for 30 min, sections were then blocked for Avidin/Biotin blocker
(Vector, Burlingame, CA, USA) for 20 min followed by 1% (v/v)
normal goat serum (NGS) (Jackson Immunoresearch Laboratories)
in 1% PBS for 20 min in room temperature. Sections were then
successfully incubated with 1.5mg/ml VT1 or 10 mg/ml VT2, mouse
anti-VT1 (PH1)(1:1000), rabbit anti-VT1B 6869 (1:2000) or rabbit
anti-VT2e (H245) (1:500) and biotinylated goat anti-mouse IgG
(1:250) or biotinylated goat anti-rabbit IgG (1:500), and Vecstatin
ABC elite reagent (Vector Burlingame). Each step consisted of a
30 min incubation followed by extensive washing with PBS. All the
toxins and antibodies were diluted in 1% NGS/PBS reagent. VT
binding was visualized with diaminobenzidine, DAB substrate
(Vector Burlingame). Sections were counterstained with Mayer’s
hematoxylin, Lillies modification (Dako, Carpintera, CA, USA),
washed with water and then dehydrated, cleared and mounted with
Permount (Sigma). Control slides were treated identically but not
exposed to the toxin.
Gp120 renal section staining
Both Triton treated and untreated human renal sections to be
stained with HIV gp120 were blocked with Universal block for
endogenous peroxidase as above. Sections were blocked with 1%
NGS/PBS for 20 min. Sections were stained with HIV-1 Bal gp120 at
1 mg/ml for 30 min at room temperature, extensively washed then
incubated with HIV-1 gp120, monoclonal antibody (F425 B4a1)
(1 mg/ml), human IgG (1:2000), and Vecstatin ABC elite reagent as
above. Gp120 binding was visualized with DAB substrate and
counterstained with hematoxylin as above. To block Gb3 receptor,
the sections were treated with 10 mg/ml VT1B for 30 min and washed
before staining with gp120.
Image analysis was performed with Image J,69 and the effect of
detergent extraction on staining was quantitated as a percentage of
untreated control ±s.d. for n measurements.
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